Triple Negative Breast Cancer

Showing NaN - NaN of 28

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Checkpoint Inhibitors in Triple Negative Breast

Recruiting
  • Triple Negative Breast Cancer
  • Whole Genome Sequencing
  • +7 more
  • Barcelona, Spain
    Vall d'Hebron Institute of Oncology
Jun 20, 2023

Triple Negative Breast Cancer, PD-L1 Negative Trial in Puerto Rico, United States (Sacituzumab Govitecan-hziy, Paclitaxel,

Recruiting
  • Triple Negative Breast Cancer
  • PD-L1 Negative
  • Sacituzumab Govitecan-hziy
  • +4 more
  • Anchorage, Alaska
  • +231 more
Jan 17, 2023

Triple Negative Breast Cancer, PD-L1 Positive Trial in Puerto Rico, United States (Sacituzumab Govitecan-hziy, Pembrolizumab,

Recruiting
  • Triple Negative Breast Cancer
  • PD-L1 Positive
  • Sacituzumab Govitecan-hziy
  • +5 more
  • Anchorage, Alaska
  • +245 more
Jan 12, 2023

NSCLC, Gastric Carcinoma, Gastroesophageal Junction Carcinoma Trial in Worldwide (SEA-TGT, sasanlimab)

Recruiting
  • Non-small Cell Lung Cancer
  • +11 more
  • Birmingham, Alabama
  • +32 more
Jan 4, 2023

Melanoma, NSCLC, Bladder Cancer Trial in Worldwide (Autogene cevumeran, Atezolizumab)

Active, not recruiting
  • Melanoma
  • +7 more
  • Scottsdale, Arizona
  • +36 more
Dec 22, 2022

Triple Negative Breast Cancer Trial in Worldwide (Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Concord, California
  • +429 more
Dec 12, 2022

Colorectal Cancer, NSCLC, Triple Negative Breast Cancer Trial in Spain, United Kingdom, United States (GEN1029

Terminated
  • Colorectal Cancer
  • +6 more
  • GEN1029 (HexaBody®-DR5/DR5)
  • New Haven, Connecticut
  • +5 more
Nov 11, 2022

HER2-negative Breast Cancer, Triple Negative Breast Cancer Trial in France, Germany, Ireland (Capecitabine, Carboplatin,

Recruiting
  • HER2-negative Breast Cancer
  • Triple Negative Breast Cancer
  • Brasschaat, Belgium
  • +161 more
Nov 2, 2022

MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma Trial in Spain (Spartalizumab)

Active, not recruiting
  • MSI-H Colorectal Cancer
  • +30 more
  • Badalona, Barcelona, Spain
  • +9 more
Oct 24, 2022

Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer Trial in Worldwide (Pembrolizumab, Lenvatinib)

Active, not recruiting
  • Advanced Solid Tumors
  • +7 more
  • Duarte, California
  • +87 more
Aug 19, 2022

Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer Trial in Worldwide (BT5528,

Recruiting
  • Advanced Solid Tumor Historically Known for High EphA2 Expression
  • +6 more
  • Encinitas, California
  • +27 more
Aug 17, 2022

Melanoma, Non-small Sell Lung Cancer (NSCLC), Triple Negative Breast Cancer Trial in Worldwide (PDR001)

Completed
  • Melanoma
  • +4 more
  • PDR001
  • Baltimore, Maryland
  • +40 more
Aug 2, 2022

Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer Trial in Worldwide (INCB106385, INCMGA00012)

Recruiting
  • Ovarian Cancer
  • +10 more
  • West Hollywood, California
  • +27 more
Jun 27, 2022

Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer Trial in Worldwide (Combination of NKTR-214 + nivolumab)

Completed
  • Melanoma
  • +6 more
  • Combination of NKTR-214 + nivolumab
  • La Jolla, California
  • +57 more
Jun 22, 2022

Triple Negative Breast Cancer Trial in Portugal, Spain (Ipatasertib, Capecitabine, Eribulin)

Recruiting
  • Triple Negative Breast Cancer
  • Amadora, Lisboa, Portugal
  • +16 more
Jun 10, 2022

HER2-negative Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer Trial in Spain (Olaparib)

Recruiting
  • HER2-negative Breast Cancer
  • +2 more
  • Barcelona, Spain
  • +4 more
Apr 14, 2022

Triple Negative Breast Cancer Trial in Worldwide (AL101)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Gilbert, Arizona
  • +28 more
Mar 31, 2022

Triple Negative Breast Cancer Trial in Spain (Carboplatin, Gemcitabine, Nadunolimab)

Recruiting
  • Triple Negative Breast Cancer
  • Málaga, Andalucía, Spain
  • +11 more
Feb 15, 2022

Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma Trial in Worldwide (MGC018, retifanlimab)

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • +5 more
  • MGC018
  • retifanlimab
  • Santa Monica, California
  • +19 more
Feb 14, 2022

Solid Tumors, NSCLC, Urothelial Carcinoma Trial in Worldwide (GEN1046, GEN1046 in combination with docetaxel (in a single

Recruiting
  • Solid Tumors
  • +6 more
  • GEN1046
  • +2 more
  • Phoenix, Arizona
  • +40 more
Jan 14, 2022

Triple Negative Breast Cancer Trial in Worldwide (SAR566658 (ACT14884))

Terminated
  • Triple Negative Breast Cancer
  • SAR566658 (ACT14884)
  • Leuven, Belgium
  • +12 more
Aug 11, 2021

Triple Negative Breast Cancer Trial in Worldwide (Cyclophosphamide, Placebo, Doxorubicin)

Completed
  • Triple Negative Breast Cancer
  • Scottsdale, Arizona
  • +157 more
Jan 15, 2021

Triple Negative Breast Cancer Trial in Worldwide (Tivozanib Hydrochloride, paclitaxel, Placebo)

Terminated
  • Triple Negative Breast Cancer
  • Tivozanib Hydrochloride
  • +2 more
  • Birmingham, Alabama
  • +53 more
Oct 5, 2020